EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Adjuvant therapy may improve overall survival in high-risk periampullary adenocarcinomas patients – A match-pair analysis from a multi-institutional cohort study (The MIPPAP study)

Anant Ramaswamy, Vikram Chaudhari, Sujay Srinivas, Prabhat Bhargava, Sadhana Kannan, Ajit Agarwal, Ramakrishnan A Seshadri, Vineet Talwar, Shaifali Goel, Varun Goel, Shivendra Singh, Smita Kayal und 21 weitere

HPB · 2024

DOI: 10.1016/j.hpb.2024.06.010 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift HPB, 2024. Verfasst von Anant Ramaswamy und 32 weiteren Autor:innen. Beteiligte Einrichtung: Dept. of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, 400012, India. Hauptthemen laut MEDLINE: Adenocarcinoma, Ampulla of Vater, Pancreatic Neoplasms, Common Bile Duct Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The role of adjuvant therapy in resected periampullary adenocarcinomas is equivocal due to contrasting data and limited prospective trials. METHODS: The Multicentre Indian Pancreatic & Periampullary Adenocarcinoma Project (MIPPAP), included data from 8 institutions across India. Of the 1679 pancreatic resections, 736 patients with T3/T4 and/or Node positive adenocarcinomas (considered as high risk for recurrence) were included for analysis. Three (adjuvant): one (observation) matching, using T3/T4 T staging, nodal positivity and ampullary subtype was performed by using the nearest neighbour matching method. RESULTS: Of 736 patients eligible for inclusion, 621 patients were matched of which 458 patients received adjuvant therapy (AT) (predominantly gemcitabine-based) and 163 patients were observed (O). With a median follow-up of 42 months, there was a statistical difference in overall survival in favour of patients receiving AT as compared to those on observation [68.7 months vs. 61.1 months, Hazard ratio: 0.73 (95% CI: 0.54-0.97); p = 0.03]. Besides AT, presence of nodal involvement (median OS: 65.4 months vs not reached; p = 0.04) predicted for inferior OS. CONCLUSIONS: The results of the match-pair analysis suggest that adjuvant therapy improves overall survival in periampullary adenocarcinomas at high risk of recurrence with a greater benefit in T3/T4, node-positive and ampullary subtypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaAmpulla of VaterPancreatic NeoplasmsCommon Bile Duct NeoplasmsNeoplasm StagingHumansMaleFemaleMiddle AgedChemotherapy, AdjuvantAgedIndiaTreatment OutcomeRisk FactorsGemcitabineTime FactorsDeoxycytidinePancreatectomyRisk AssessmentAdult

Substanzen

GemcitabineDeoxycytidine

Autor:innen und Institutionen

  • Dept. of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, 400012, India.
  • Dept. of GI & HPB Surgery, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Dr. E Borges Road, Parel, Mumbai, 400 012, India.
  • Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
  • Department of Statistics, Advanced Centre for Treatment, Research and Education in Cancer, Homi Bhabha National Institute (HBNI), Mumbai, India.
  • BALCO Medical Centre, Sector-36, P.O. Uparwar, Naya Raipur, Chattisgarh, 493661, India.
  • Cancer Institute (WIA), Dr. S Krishnamurthy campus, No.38, Sardar Patel Road, Chennai, 600036, India.

Zitieren

APA

Ramaswamy, A., Chaudhari, V., Srinivas, S., Bhargava, P., Kannan, S., Agarwal, A., Seshadri, R. A., Talwar, V., Goel, S., Goel, V., Singh, S., Kayal, S., Rebala, P., Rao, G. V., Prajapati, B., Parikh, D., Kothari, J., Kadamapuzha, J. M., Ramesh, H., …, & Ostwal, V. (2024). Adjuvant therapy may improve overall survival in high-risk periampullary adenocarcinomas patients – A match-pair analysis from a multi-institutional cohort study (The MIPPAP study). HPB. https://doi.org/10.1016/j.hpb.2024.06.010

Vancouver

Ramaswamy A, Chaudhari V, Srinivas S, Bhargava P, Kannan S, Agarwal A, et al. Adjuvant therapy may improve overall survival in high-risk periampullary adenocarcinomas patients – A match-pair analysis from a multi-institutional cohort study (The MIPPAP study). HPB. 2024. doi:10.1016/j.hpb.2024.06.010

BibTeX
@article{Ramaswamy2024,
  author = {Ramaswamy, Anant and Chaudhari, Vikram and Srinivas, Sujay and Bhargava, Prabhat and Kannan, Sadhana and Agarwal, Ajit and Seshadri, Ramakrishnan A and Talwar, Vineet and Goel, Shaifali and Goel, Varun and Singh, Shivendra and Kayal, Smita and Rebala, Pradeep and Rao, G V and Prajapati, Bharat and Parikh, Devendra and Kothari, Jagdish and Kadamapuzha, Jacob M and Ramesh, Hariharan and Kapoor, Deeksha and Chaudhary, Adarsh and Gupta, Amit and Sekar, Anbarasan and Misra, Sanjeev and Vishnoi, Jeewan R and Soni, Subhash and Varshney, Vaibhav K and Bairwa, Sandeep K and Ghosh, Joydeep and Lavingia, Viraj and Bhandare, Manish and Shrikhande, Shailesh V and Ostwal, Vikas},
  title = {Adjuvant therapy may improve overall survival in high-risk periampullary adenocarcinomas patients – A match-pair analysis from a multi-institutional cohort study (The MIPPAP study)},
  journal = {HPB},
  year = {2024},
  doi = {10.1016/j.hpb.2024.06.010}
}
Kostenlos starten →